证券代码：000963 证券简称：华东医药 公告编号：2023-060 华东医药股份有限公司 第十届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华东医药股份有限公司（以下简称"公司"） 第十届董事会第十 四次会议的通知于2023年8月4日以书面、电子邮件的方式送达各位董 事，于2023年8月9日以现场并结合通讯表决方式召开。会议应参加董 事9名，实际参加董事9名。本次会议的召开和表决程序符合《公司法》、 《公司章程》的有关规定，会议合法有效。 华东医药股份有限公司董事会 于全资子公司与Arcutis公司签署产品独家许可协议的公告》，公告编 号：2023-061）。 2、同意授权管理层负责签署本次交易有关协议及具体履行协议 的相关事宜，授权期限至相关事宜全部办理完毕止。 3、独立董事已就本次交易发表了独立意见。 议案表决结果：同意：9 票，反对：0 票，弃权 0 票。 根据深圳证券交易所《股票上市规则》和《公司章程》的有关规 定，上述事项经公司董事会审议通过后即可实施，无需提交公司股东 大会审议。 特此公告。 本次董事会就以下议案 ...

3、本次交易符合公司科研创新转型的战略，有助于进一步提升公司 在自身免疫领域竞争力，有利于全体股东的长远利益。 独立董事： 华东医药股份有限公司独立董事 关于第十届董事会第十四次会议相关事项的独立意见 根据中国证监会《上市公司独立董事规则》、《深圳证券交易所股 票上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号——主 板上市公司规范运作》及华东医药股份有限公司（以下简称"公司"） 《独立董事工作制度》的有关规定，我们作为公司的独立董事，基于独 立判断立场，在认真审议公司《关于全资子公司与 Arcutis 公司签署产品 独家许可协议的议案》基础上，本着独立性、客观性、公正性的原则， 现发表独立意见及有关说明如下： 1、董事会对于本次交易事项进行了充分沟通，决策程序合法； 2、本次交易公司对目标公司进行了全面的尽职调查，交易作价及相 关商务条款经合作各方协商确定，公允合理，不存在损害上市公司和中 小股东利益的情形； 高向东 黄 简 王如伟 2023 年 8 月 11 日 ...

证券代码：000963 证券简称：华东医药 公告编号：2023-061 华东医药股份有限公司 关于全资子公司与 Arcutis 公司签署产品独家许可协议的公告 2023 年 8 月 10 日，公司全资子公司中美华东与美国上市公司 Arcutis 签订了产品独家许可协议（以下简称"《合作协议》"）。中美 华东获得 Arcutis 全球创新的罗氟司特外用制剂（包括罗氟司特乳膏 剂 ZORYVE®和罗氟司特泡沫剂 ARQ-154）（以下简称"许可产品"） 在大中华区（含中国大陆，香港、澳门和台湾地区）及东南亚（印度 尼西亚、新加坡、菲律宾、泰国、缅甸、文莱、柬埔寨、老挝、马来 西亚和越南）（以下简称"许可区域"）的独家许可，包括开发、注册、 生产及商业化权益。中美华东将向 Arcutis 支付 3,000 万美元首付款， 1 最高不超过 6,425 万美元的开发、注册及销售里程碑付款，以及分级 两位数的净销售额提成费（以下简称"本次交易"）。 公司董事会以 9 票同意，0 票弃权，0 票反对审议通过了本次交 易。 本次交易不构成关联交易，亦不构成《上市公司重大资产重组管 理办法》规定的重大资产重组。根据深交所《股票 ...

证券代码：000963 证券简称：华东医药 | --- | --- | |------------|----------------------------------------------------| | | 编号：2023-008 | | | 分析师会议 | | 投资者关系 | 业绩说明会 | | 活动类别 | | | | 现场调研 | | | 华泰证券、国寿资产、瑞银证券、国泰资产、西部证券、 | | 参与单位名 | 、StoneyLake Asset | | 称及人员姓 | 、The Carlyle Group、BPEA EQT | | 名 | 、Sumitomo trust、Open door、Superstring | | | | 时间 2023 年 6 月 13 日 15:00-16:30、2023 年 6 月 15 日 13:00-14:00、2023 年 6 月 16 日 13:00-14:00 地点 公司会议室 上市公司接 待人员姓名 公司董事会秘书陈波 问题 1：利拉鲁肽糖尿病适应症目前的销售情况？减肥适应症的 获批时限？ 答：公司利拉鲁肽注射液（糖尿病适应症）正在全国各省积极开展 ...

华东医药股份有限公司投资者关系活动记录表 1 证券代码：000963 证券简称：华东医药 编号：2023-007 | --- | --- | --- | --- | |-------------------|-------------------------------------------------|--------------------------------------------------------------|----------------------------------------| | | | | | | 投资者关系 | □ 特定对象调研 | □分析师会议 | | | 活动类别 | □ 媒体采访 □ 新闻发布会 | 业绩说明会 □路演活动 | | | | □ 现场参观 | □ 其他 | | | | | | | | 参与单位名 | 华东医药 2022 年度及 参与单位：机构和个人投资者 | 2023 年第一季度网上业绩说明会 29 人。 | | | 称及人员姓 | | | | | 名 时间 | 2023 年 5 月 12 日 | 15:00-17:00 | | | 地点 | 公司会 ...

证券代码：000963 证券简称：华东医药 编号：2023-006 | --- | --- | --- | |------------|---------------|--------------------------| | | □特定对象调研 | □分析师会议 | | 投资者关系 | □媒体采访 | □业绩说明会 | | 活动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | 其他公司投资者接待日活动 | 参与单位：中金公司、中信证券、华泰证券、高毅资产、安信证券、 国信证券、瑞银证券、东吴证券、浙商证券、天风证券、东玛基金、 国寿养老、人保资产、长城国瑞证券、杭银理财、建信期货、中邮创 参与单位名 业、京港伟业投资、大筝资产、金辇投资、莫尼塔咨询、波粒二象资 称及人员姓 管、景林资产、汇森投资、初樱基金、九水投资、安博投资、合众易 名 晟投资、涌津投资、清池资本、东方马拉松、优益增投资、世峰投资、 上海德汇集团、中证中小投资者服务中心有限责任公司等机构和个人 投资者 92 人。 时间 2023 年 5 月 8 日 15:30-17:30 地点 公司会议室 公司董事长兼总经理吕梁、公司副总 ...

证券代码：000963 证券简称：华东医药 公告编号：2023-035 华东医药股份有限公司 关于参加浙江辖区上市公司2023年投资者网上集体接待日活动 暨召开网上业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，华东医药股份有限公司（以下 简称"公司"）将参加由浙江证监局、浙江省上市公司协会与深圳市全 景网络有限公司联合举办的"2023 年浙江辖区上市公司投资者集体接待 日活动" 暨召开 2022 年度及 2023 年第一季度网上业绩说明会，现将相 关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演" 网站（ https://rs.p5w.net ） 或 直 接 进 入 公 司 路 演 厅 （http://ir.p5w.net/c/000963.shtml），或关注微信公众号：全景财经，或 下载全景路演 APP，参与本次互动交流，活动时间为 2023 年 5 月 12 日 （周五）15:00-17:00。 届时公司董事长兼总经理吕梁先生、董事会秘书陈波先生、财务负 责人邱仁波先生（如有特殊情 ...

Financial Performance - In Q1 2023, the company achieved revenue of 10.115 billion CNY, marking a year-on-year increase of 13.23% and a quarter-on-quarter growth of 2.62% [4] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 855 million CNY, up 14.99% year-on-year [4] - The core subsidiary, China Medical East, reported revenue of 3.075 billion CNY, a 10.19% increase year-on-year, and a net profit of 667 million CNY, up 15.90% [4] - The pharmaceutical commercial segment generated revenue of 6.844 billion CNY, reflecting a year-on-year growth of 15.67% [4] - The medical aesthetics segment achieved revenue of 503 million CNY, a 10.86% increase year-on-year [4] Product Development - ELAHERE™ for ovarian cancer is set to submit a BLA application in 2023 after completing Phase III clinical trials [5] - HDM3002 (PRV-3279) is undergoing Phase IIa trials for systemic lupus erythematosus (SLE) [5] - The company has submitted IND applications for HDM1002 and GLP-1 receptor agonists in 2023 [6] Market Expansion - The company acquired a 70% stake in Jiangsu Nanjing Agricultural University Animal Medicine Co., Ltd. for 265 million CNY, aiming to enhance its presence in the animal health sector [11][12] - The pet health market has seen a compound annual growth rate (CAGR) exceeding 34% from 2016 to 2021, indicating significant growth potential [11] International Operations - The UK subsidiary, Sinclair, reported revenue of 3.38 million GBP (approximately 284 million CNY), with an 8.89% year-on-year increase [6] - The company is expanding its global medical aesthetics market presence, with expectations of improved performance in Q2 2023 [5] R&D and Innovation - The company has over 130 ongoing R&D projects in the industrial microbiology sector, with 78 authorized patents and 51 pending [9] - The establishment of Hunan Huixin Biotechnology Co., Ltd. focuses on mRNA drug manufacturing and CRO/CDMO services [10] Financial Outlook - The company anticipates a stable financial environment starting Q2 2023, with a reduction in financial costs due to loan repayments [15]

Financial Performance - The company's revenue for Q1 2023 was ¥10,114,531,331.77, representing a 13.23% increase compared to ¥8,932,579,251.75 in the same period last year[3]. - Net profit attributable to shareholders was ¥755,284,976.47, up 7.23% from ¥704,364,775.13 year-on-year[3]. - Basic earnings per share increased to ¥0.4316, reflecting a 7.23% rise from ¥0.4025 in the same period last year[3]. - Total operating revenue for Q1 2023 reached ¥10,114,531,331.77, an increase of 13.2% compared to ¥8,932,579,251.75 in the same period last year[59]. - The net profit attributable to the parent company was CNY 755.28 million, compared to CNY 704.36 million in the previous year, representing an increase of approximately 7.25%[61]. - The company reported a net profit of CNY 759.93 million, an increase from CNY 714.03 million, marking a growth of about 6.4%[60]. - The total profit amounted to CNY 949.28 million, up from CNY 883.19 million, representing an increase of approximately 7.5%[60]. Cash Flow and Financial Position - The net cash flow from operating activities was -¥246,152,770.16, an improvement of 5.55% compared to -¥260,603,628.32 in the previous year[3]. - The company's cash and cash equivalents decreased to ¥2,375,152,352.20 from ¥3,996,302,178.41, a decline of approximately 40.6%[57]. - The net cash flow from financing activities was -¥849,412,643.67, a drastic decline of 15,173.65% compared to -¥5,561,294.58 in the previous year[7]. - The ending balance of cash and cash equivalents was 1,885,818,947.15 CNY, down from 2,719,653,285.63 CNY at the end of Q1 2022[64]. - The company reported a total cash outflow of 1,648,297,397.71 CNY related to other operating activities, up from 1,426,599,607.70 CNY in Q1 2022[63]. Assets and Liabilities - Total assets at the end of the reporting period were ¥32,115,200,767.26, a 2.96% increase from ¥31,192,203,406.84 at the end of the previous year[3]. - Accounts receivable increased to ¥8,634,543,140.84 from ¥7,198,746,788.59, reflecting a growth of approximately 20.0%[57]. - Inventory rose to ¥5,055,660,372.20, up from ¥4,495,483,328.54, indicating an increase of about 12.5%[57]. - Current liabilities totaled ¥10,627,556,249.33, an increase from ¥10,152,812,095.73, representing a rise of about 4.7%[58]. - Long-term borrowings decreased to ¥677,604,268.25 from ¥1,051,457,747.44, a reduction of about 35.5%[58]. Research and Development - R&D investment in the pharmaceutical sector reached 387 million RMB, with direct R&D expenses of 306 million RMB and equity investments in product development of 81 million RMB[13]. - The company has established a robust innovation drug R&D team with over 500 core technical talents, focusing on various drug types including small molecules and ADCs[25][26]. - The company aims to develop at least 10 innovative ADC products from 2022 to 2024, with 6 projects already initiated in preclinical or exploratory stages[28]. - The company has established over 40 innovative drug research and development projects in the global R&D center since its inception three years ago, with 6 self-developed PCC molecules and 6 IND approvals[35]. Product Development and Pipeline - The company is advancing the ELAHERE™ product for ovarian cancer, with plans to submit a BLA application within the year following successful clinical trials[14]. - The company is conducting a Phase IIa clinical trial for HDM3002, aimed at treating systemic lupus erythematosus (SLE), with an IND application submitted in February 2023[15]. - The company is advancing its ADC pipeline, including HDM2002 (ELAHERE™), which received FDA accelerated approval for platinum-resistant ovarian cancer, with plans to submit a BLA application in 2023[28]. - The company is developing a GLP-1 targeted platform for obesity and diabetes, with 4 clinical projects and 2 IND development projects, aiming to expand indications beyond diabetes[30]. Market Expansion and Strategy - The company aims to maintain rapid revenue growth throughout 2023, supported by ongoing market expansion and product development efforts[10]. - The company aims to integrate R&D, manufacturing, and marketing to enhance its international medical beauty business and introduce high-potential products into the Chinese market[56]. - The company has established a global marketing network covering over 80 countries, with a specialized team of nearly 300 professionals[56]. - The company aims to enhance its product quality and expand new product pipelines by serving nearly 1,000 industry and research clients[42]. Financial Challenges - The company reported a significant increase in financial expenses, which rose by 261.66% to ¥29,150,841.84 due to higher net interest expenses[7]. - The company incurred financial expenses of CNY 29.15 million, significantly higher than CNY 8.06 million in the previous year, indicating an increase of about 261.5%[60]. - The company experienced an investment loss of CNY 61.75 million, worsening from a loss of CNY 27.96 million in the previous year[60].